Carmot Therapeutics: Funding, Investors & Team (Sep 2026)
Carmot Therapeutics gives medications to treat incendiary, metabolic, and neurological infections. They utilize their protected innovation, Chemotype Evolution, to address the crucial reasons for sickness and speed the revelation of infection changing treatments. Carmot Therapeutics is settled in San Francisco, California and was established in 2008.
Carmot Therapeutics has raised $160M across 1 funding round on record, the most recent a Series D of $160M announced in Jul 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Carmot Therapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2022.
Carmot Therapeutics Funding Rounds
Carmot Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Carmot Therapeutics Funding Compared to Other Biotechnology Startups
Carmot Therapeutics' latest round of $160M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Carmot Therapeutics in Biotechnology and San Francisco
Companies Similar to Carmot Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Carmot Therapeutics Funding FAQs
What does Carmot Therapeutics do?
Carmot Therapeutics gives medications to treat incendiary, metabolic, and neurological infections. They utilize their protected innovation, Chemotype Evolution, to address the crucial reasons for sickness and speed the revelation of infection changing treatments. Carmot Therapeutics is settled in San Francisco, California and was established in 2008.
How much funding has Carmot Therapeutics raised?
Carmot Therapeutics has raised $160M across 1 round on record. The most recent is a Series D of $160M announced in Jul 2022.
When did Carmot Therapeutics last raise funding?
Carmot Therapeutics' most recent funding round on record is a Series D of $160M, announced in Jul 2022.
Who is the CEO of Carmot Therapeutics?
Stig K Hansen is listed as CEO at Carmot Therapeutics.
Where is Carmot Therapeutics headquartered?
Carmot Therapeutics is based in San Francisco, California, United States.
How many employees does Carmot Therapeutics have?
Carmot Therapeutics is in the 1-10 employee band.
How does Carmot Therapeutics' funding compare to other Biotechnology startups?
Carmot Therapeutics' latest round of $160M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Carmot Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Carmot Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.